The Level of HBV DNA at Month 12 Is an Important Predictor of Virological Breakthrough During Adefovir Monotherapy in Chronic Hepatitis B Patients with Lamivudine Resistance

Moon-Chan Kim; Seok Won Jung; Jung Woo Shin; Neung Hwa Park

首页> 外文期刊>Digestive Diseases and Sciences >The Level of HBV DNA at Month 12 Is an Important Predictor of Virological Breakthrough During Adefovir Monotherapy in Chronic Hepatitis B Patients with Lamivudine Resistance

【24h】

The Level of HBV DNA at Month 12 Is an Important Predictor of Virological Breakthrough During Adefovir Monotherapy in Chronic Hepatitis B Patients with Lamivudine Resistance

机译：第12个月HBV DNA水平是阿德福韦酯单药治疗对拉米夫定耐药的慢性乙型肝炎患者病毒学突破的重要预测指标

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background and Aims The aim of this study was to determine the optimal time and HBV DNA levels during the treatment period for prediction of virological breakthrough (VBT) 3 years after adefovir monotherapy in chronic hepatitis B (CHB) patients with lamivudine resistance.

机译：背景与目的本研究的目的是确定治疗期间的最佳时间和HBV DNA水平，以预测阿德福韦单药治疗拉米夫定耐药的慢性乙型肝炎（CHB）患者3年后的病毒学突破（VBT）。

著录项

来源
《Digestive Diseases and Sciences》 |2011年第4期|p.1215-1221|共7页
作者
Moon-Chan Kim; Seok Won Jung; Jung Woo Shin; Neung Hwa Park;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Hepatitis B virus – Adefovir dipivoxil – Lamivudine resistance – HBV DNA level;

机译：乙肝病毒–阿德福韦酯–拉米夫定耐药– HBV DNA水平;

相似文献

外文文献
中文文献
专利

1. The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance. [J] . Kim MC, Jung SW, Shin JW, Digestive Diseases and Sciences . 2011,第4期

机译：在患有拉米夫定耐药的慢性乙型肝炎患者中，阿德福韦单药治疗期间12个月的HBV DNA水平是病毒学突破的重要预测指标。
2. Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: A 5-year study of patients with hepatitis B with lamivudine resistance [J] . IkedaF., BabaN., TakaguchiK., Journal of Medical Virology . 2012,第10期

机译：乙型肝炎e抗原可预测阿德福韦酯和拉米夫定不会导致病毒突破而延迟HBV DNA减少：一项对拉米夫定耐药的乙型肝炎患者的5年研究
3. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: A retrospective, multicenter, nonrandomized, open-label st [J] . Pellicelli AM, Barbaro G, Francavilla R, Clinical therapeutics . 2008,第2期

机译：阿德福韦和拉米夫定联合阿德福韦单药治疗慢性乙型肝炎病毒感染且对拉米夫定具有临床或病毒学耐药性的HBeAg阴性成人：回顾性，多中心，非随机，开放标签的研究
4. Adefovir dipivoxil for the treatment of chronic hepatitis B infection and in vitro evaluation of hte cross-resistance profiles of lamivudine,famciclovir and adefovir [C] . X Xiong, A Murray, H Yang, Second workshop related to HIV/AIDS in China . 1999

机译：阿德福韦酯对慢性乙型肝炎感染的治疗以及拉米夫定，泛昔洛韦和阿德福韦的交叉耐药性的体外评估
5. Virologic Response at 12 Months of Treatment Predicts Sustained Antiviral Efficacy in Patients with Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B [O] . Young Kul Jung, Jong Eun Yeon, Woo Sik Han, 2010

机译：治疗12个月时的病毒学应答预测阿德福韦治疗的抗拉米夫定的慢性乙型肝炎患者的抗病毒疗效持续
6. Virologic Response at 12 Months of Treatment Predicts Sustained Antiviral Efficacy in Patients with Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B [O] . Jung, Young Kul, Yeon, Jong Eun, Han, Woo Sik, 2010

机译：治疗12个月时的病毒学应答预测阿德福韦治疗的抗拉米夫定的慢性乙型肝炎患者的抗病毒疗效持续

The Level of HBV DNA at Month 12 Is an Important Predictor of Virological Breakthrough During Adefovir Monotherapy in Chronic Hepatitis B Patients with Lamivudine Resistance

摘要

著录项

相似文献

相关主题

期刊订阅